---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116346"
form_type: "8-K"
ticker: "ZBIO"
cik: "0001953926"
company_name: "Zenas BioPharma, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:20:07.343686+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zenas Q3 2024: Net loss $38.6M; raised $258.7M IPO; obexelimab INDIGO topline by end 2025

## Summary
- Completed IPO raising $258.7M gross proceeds; cash $386.8M to fund into Q4 2026.
- Phase 3 INDIGO (IgG4-RD) completed enrollment; topline results expected by end 2025.
- Initiated Phase 2 MoonStone (RMS) and SunStone (SLE); MoonStone results Q3 2025, SunStone topline H1 2026.
- Net loss $38.6M vs net income $35.6M (prior year had BMS collaboration); R&D $33.5M vs $9.4M.
- Appointed CCO Orlando Oliveira and CLO Jeff Held; out-licensed ZB005 for upfront and milestones.

## SEC filing metadata
- accession: 0001104659-24-116346
- form_type: 8-K
- ticker: ZBIO
- cik: 0001953926
- company_name: Zenas BioPharma, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/0001104659-24-116346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116346
- JSON: https://secwatch.observer/filing/0001104659-24-116346.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.